Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
